Dr. Bing Yao is a Professor and Deputy Director of the Experimental Teaching Center at Nanjing Medical University, specializing in tumor biology with a focus on metal-dependent cell death and epigenetic regulation mechanisms in cancer. He earned his Ph.D. from the School of Life Sciences at Nanjing University, where he developed a strong foundation in molecular biology and cancer genetics. Dr. Yao has led multiple research projects funded by the National Natural Science Foundation of China and other national programs, advancing understanding of molecular pathways driving tumor resistance and progression. His pioneering studies on ferroptosis, cuproptosis, and chromatin modification have been published in leading international journals, including Cancer Cell, Advanced Science, Cell Reports, Genome Medicine, and Molecular Cancer, where he has served as senior or corresponding author. In recognition of his outstanding scientific achievements, he has received numerous honors such as the Jiangsu Provincial Science and Technology Award, the Youth Science and Technology Talent Support Program, and the Excellent Young Backbone Teacher Award under the “Qinglan Project.” Dr. Yao is also actively involved in academic mentorship, guiding students who have won multiple national and international innovation awards. His editorial roles, professional memberships, and certifications further reflect his leadership and commitment to advancing biomedical research and education in oncology and molecular medicine.
Profile: ORCID
Featured Publications
Bing Yao*, PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. Genome Med., 2021, 13(1), 71.
Bing Yao*, CircEZH2/miR133b/IGF2BP2 aggravates colorectal cancer progression via enhancing the stability of m6A-modified CREB1 mRNA. Mol. Cancer, 2022, 21(1), 140.
Bing Yao*, KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc. Clin. Transl. Med., 2024, e1573.
Bing Yao*, The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression. Mol. Cancer, 2022, 21(1), 119.